(Yicai) Aug. 11 -- Twenty-nine Chinese securities will be added to the MSCI China Indexes and 19 medical stocks removed, including Jafron Biomedical and Zhejiang Wolwo Bio-Pharmaceutical, global index compiler MSCI said following its monthly review.

Jafron [SHE: 300529] closed down 1.7 percent at CNY23 (USD3.20), Zhejiang Wolwo [SHE: 300357] dropped 1.3 percent to CNY34.78, and Hangzhou Tigermed Consulting [SHE: 300347] fell 1.2 percent to CNY68.98.

Twenty-eight Chinese mainland-listed firms, including vehicle makers such as Anhui Jianghuai Automobile Group, BAIC BluePark New Energy Technology, Beiqi Foton Motor, and Yutong Bus will be added along with one traded in Hong Kong, Sinotruk Hong Kong.

There will also be 10 additions and 50 deletions from the MSCI China A Onshore Index, which tracks large and mid-cap stocks in Shanghai and Shenzhen. The three largest joiners will be CNPC Capital, electrical equipment maker Gongniu Group, and Eastroc Beverage Group.

CanSino Biologics, a company that develops, makes, and sells vaccines and has a market capitalization of more than CNY20 billion (USD2.8 billion), will be deleted from the MSCI China A Onshore Index. Its shares [SHA: 688185] fell 2.9 percent to about CNY89.84.

The inclusion of these securities into the MSCI China Indexes heralds their induction into the MSCI Global Standard Indexes, so they will attract a huge passive, index-tracking funds.

The changes will take effect after stock markets close on Aug. 31.

Editor: Peter Thomas